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Abstract 
Purpose: To investigate the anti-proliferative effect of puerarin on retinoblastoma cells. 
Methods: The effect of puerarin was examined on human retinoblastoma Y79 cells using cell 
proliferation assays and reverse transcription-polymerase chain reaction (RT-PCR). The effect of 
puerarin on the cell cycle was also investigated. Western blot and RT-PCR analyses were also 
performed to identify the putative mechanism of action.  
Results: The results showed that cell viability was suppressed by puerarin in a concentration-
dependent manner with a half-maximal inhibitory concentration (IC50) of 0.184 ± 0.034 μmol/L. 
Moreover, puerarin increased the proportion of cells in G1 phase from 42.6 ± 3.1 to 62.83 ± 4.1, 75.76 ± 
3.4 and 91.33 ± 5.1 % in a concentration-dependent manner at concentrations of 0.1, 0.2, and 0.4 
μmol/L, respectively. The results also indicate that Bmi-1 mRNA and protein levels decreased after 
puerarin treatment. Additionally, flow cytometry data showed that Bmi-1 knock-down through siRNA 
resulted in G1-cell cycle arrest. The proportion of cells in G1 were 51.2 ± 2.5 and 71.4 ± 4.5 % for 
control and Bmi-1 siRNA-treated groups, respectively. 
Conclusions: The results show that puerarin exert suppressive effects on human retinoblastoma Y79 
cells and therefore may find application in the treatment of intraocular tumor. 
 
Keywords: Cancer, Puerarin, Retinoblastoma Y79 cells, mTOR inhibition, Intraocular tumor 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Cancer is one of the deadliest diseases known to 
mankind, and despite improvements in treatment 
remains a leading cause of death worldwide 
[1,2]. Retinoblastoma is a malignant intraocular 
tumor that affects infants and children [3]. If 
undiagnosed or untreated, patients with 
retinoblastoma die within two years due to 
intracranial extensions of the tumor [4]. The 
primary treatment consists of chemo-reduction 
with local consolidation with or without systemic 
chemotherapy [5]. However, all available 
therapies have major limitations and the use of 
chemotherapy can be challenging in pediatric 
patients [6]. Consequently, there is a pressing 
need to develop new therapeutic options to 
improve the outcomes of patients diagnosed with 
retinoblastoma. Natural products or derivatives 
are often good sources of agents that associated 
are with numerous biological activities [7]. These 
derivatives have high therapeutic activity due to 
their high chemical and molecular diversity. They 
are also associated with biochemical specificity 
and optimal molecular characteristics that make 
them promising targets for future drug discovery 
[8]. Out of the millions of naturally occurring 
compounds, only a few have been developed for 
use as cancer therapies [9]. These include vinca 
alkaloids [10], paclitaxel, docetaxel [11], 
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etoposide, teniposide [12], and camptothecin and 
camptothecin derivatives, topothecan, 
irinothecan [13], and anthracycline [14].    
 
Therefore, we aimed to elucidate the anti-
proliferative effects of Puerarin on retinoblastoma 
cells [15]. Puerarin is a major bioactive ingredient 
obtained from the Puerarialobata (Willd.) Ohwi 
root [16]. It is widely known as Gegen in 






Puerarin (98 %), rapamycin, penicillin, 
streptomycin, propidium iodide (PI), and other 
chemicals were purchased from Sigma Chemical 




Roswell Park Memorial Institute (RPMI) 1640 
medium was purchased from Gibco BRL 
(Waltham, US), fetal bovine serum (FBS) was 
obtained from Life Technologies Corporation 
(Shanghai, China), and cell counting kit-8 (CCK-
8) was obtained from Beyotime Corporation 
(Jiangsu, China). Mammalian target of rapamycin 
(mTOR), phosphorylated-mTOR (p-mTOR), 
cyclin E1, Bmi-1, and β-actin antibodies were 
procured from Cell Signaling Technology Inc 
(Shanghai, China). Primer sequences, including 
specific siRNA sequences for Bmi-1 and 
nonspecific control siRNA, were designed and 
developed by GenePharma Co. Ltd (Shanghai, 
China). An Avian Myeloblastosis Virus (AMV) 
reverse transcriptase system was purchased 
from Promega (Wisconsin, United States). 
 
Cell lines and cell culture 
 
The human retinoblastoma cell line Y79 (ATCC, 
USA) was cultured in RPMI 1640 medium 
supplemented with 10 % FBS, 1 % penicillin, and 
streptomycin at 37 °C in a humidified incubator 
containing 5 % CO2. 
 
Cell proliferation assays 
 
To determine cell proliferation, the CCK-8 assay 
was used to assess cell viability. Briefly, the cells 
were seeded in 96-well plates with an average of 
3, 000 cells per well for 24 h. Ten microliters of 
rapamycin was then diluted with culture medium 
and different concentrations of puerarin were 
added to the wells for an additional 48 h. After 
that, 10 μL of CCK-8 solution was added to each 
well and incubated at 37 °C for an additional 2 h. 
The optical density (OD) value of the solution 
was then evaluated at 450 nm, and the IC50 
values were calculated from the survival curve. 
The entire experiment was replicated three 
times. 
 
Puerarin effect on the cell cycle  
 
Briefly, Y79 cells were treated with different 
concentrations of puerarin for 48 h. The treated 
cells were then trypsinized, washed in PBS, and 
fixed in ice-cold 75 % ethanol/PBS. The resulting 
cells were stained with Propidium Iodide (PI) for 
30 min and were analyzed by flow cytometry 
(Beckman Coulter, Inc). The corresponding cell 
cycle profiles were determined using MultiCycle 
AV software. All experiments were replicated 
three times. 
 
Western blot analysis 
 
Briefly, Y79 cells were treated with various 
concentrations of puerarin for 48 h, and then 
lysed using cold lysis buffer. The resulting cell 
lysates were centrifuged at 10, 000 rpm for 20 
min, and the supernatant was collected. Fifty 
micrograms of protein lysate was then separated 
using an 8-12 % SDS-PAGE gel and later 
transferred onto a PVDF membrane (Millipore, 
USA). The loaded membrane was blocked with 5 
% non-fat milk powder (w/v) in tris-buffered 
saline with tween (TBST) (10 mm Tris, 100 mm 
NaCl, 0.1 % Tween 20) for 2 h, and then 
incubated with primary antibodies at 4 °C 
overnight. Subsequently, suitable HRP-linked 
secondary antibodies were added and incubated 
for an additional 1 h.  Lastly, Western Blotting 
Luminal Reagent (Millipore) was used for the 
detection of specific protein bands using β-actin 
as an endogenous control. All experiments were 




Y79 cells were treated with the desired 
concentrations of puerarin for 48 h before 
extracting total RNA. The single-stranded cDNA 
was reverse transcribed using the AMV Reverse 
Transcriptase System, and the PCR reactions 
were performed using an ABI Prism 9700 PCR 
System. For cDNA development, 35 cycles (94 
°C; 30 s, 60 °C; 30 s, and 72 °C; 1 min) were 
used and the PCR primers selected were 5’-GTA 
TTC CCT CCA CCT CTT CTT G-3’ (forward) and 
5’-TGC TGA TGA CCC ATT TAC TGA T-3’ 
(reverse) for Bmi-1, and 5’-GGG ACC TGA CTG 
ACT ACC TCA-3’ (forward) and 5’-GAC TCG 
TCA TAC TCC TGC TTG-3’ (reverse) for β-actin 
(control), respectively. The reactions were 
replicated three times. 
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Bmi-1 siRNA studies  
 
siRNA was transfected using Lipofectamine 2000 
in accordance with the manufacturer’s instruc-
tions. Briefly, 5 × 105 Y79 cells were plated in six-
well plates and transfected with 50 nmol/L Bmi-1 
or negative control siRNA duplex components 
using 5 μL Lipofectamine 2000 per well. The 
cells were incubated for 48 h, and the total 
extracted protein was subjected to Western blot 




Data were statistically analyzed using Graphpad 
Prism software. Independent t-test was used 
between two groups, and comparisons among 
multiple groups were performed using a one-way 
analysis of variance (ANOVA) followed by 





Effect of puerarin on the proliferation of 
human retinoblastoma Y79 cells 
 
In this assay, we investigated the effect of 
puerarin on the proliferation of human 
retinoblastoma Y79 cells. We treated the cells 
with various concentrations of puerarin, (0.1, 0.2, 
and 0.4 μmol/L) for 48 h using a CCK-8 assay. 
The results show that cell viability was 
suppressed by puerarin in a concentration-
dependent manner. The IC50 of puerarin (0.184 ± 
0.034 μmol/L) further indicated the potent 
inhibitory potential of puerarin on human 
retinoblastoma Y79 cells. 
 
Effect of puerarin on the cell cycle in human 
retinoblastoma Y79 cells 
 
In this assay, Y79 cells were treated with or 
without puerarin for 48 h. The puerarin 
concentrations used were: 0.1, 0.2, and 0.4 
μmol/L. After treatment, the cells were fixed, 
nuclear DNA was stained with PI, and flow 
cytometry was used to determine the population 
of cells in each cell cycle stage. As shown in 
Figure 1A, the percentage of cells in G1 and S 
increased and decreased, respectively, after 
treatment with puerarin. As shown in Figure 1, 
the percentage of cells in G1 increased from 42.6 
± 3.1 to 62.83 ± 4.1, 75.76 ± 3.4 and 91.33 ± 5.1 
% at concentrations of 0.1, 0.2, and 0.4 μmol/L, 
respectively (Figure 1B). The results suggest that 
puerarin results in G1 arrest in a time-dependent 
manner. 
 
Figure 1: Effect of puerarin on cell cycle phase in human retinoblastoma Y79 cells;*p < 0.05; **p < 
0.01 compared with respective controls (n = 3) 
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Effect of puerarin on mTOR phosphorylation 
in human retinoblastoma Y79 cells 
 
The role of mTOR in the progression of human 
cancers has been shown and reviewed in 
multiple previous studies. Thus, in this study, we 
analyzed the effect of puerarin on mTOR protein 
levels in human retinoblastoma Y79 cells by 
Western blot analysis. As depicted in Fig. 2A, 
administration of puerarin resulted in decreased 
phosphorylation of mTOR (p-mTOR) and had no 
effect on overall mTOR levels. The results of the 
Western blot analysis confirmed that puerarin 
effectively attenuated the mTOR pathway 
signaling in Y79 cells. 
 
 
Figure 2: Effect of puerarin on protein 
expression determined by Western blot analysis. 
A) Inhibition of the mTOR pathway via puerarin 
and reduction of BMI-1 and cyclin E1 proteins. B) 
Puerarin decreased mRNA expression of Bmi-1. 
 
Effect of puerarin on Bmi-1 and cyclin E1 
protein levels 
 
Various studies have described the role of cyclin 
E1 in the progression of G1/S phase and the 
downregulation of this action through the mTOR 
pathway [17]. Therefore, we examined the effect 
of puerarin on cyclin E1 expression by Western 
blot analysis (Fig. 2A). The results show that 
puerarin results in cyclin E1 downregulation. The 
results also indicate that Bmi-1 protein and 
mRNA levels were reduced after treatment with 
puerarin. This suggests that the inactivation of 
Bmi-1 and downregulation of cyclin E1 could be 
responsible for mTOR inhibition. 
 
Bmi-1 siRNA reduced cyclin E1 levels and 
subsequently amplified the percentage of 
cells in G1 phase 
 
Lastly, we investigated the effect of Bmi-1 
inhibition on human retinoblastoma Y79 cell 
viability. The cells were transfected with specific 
Bmi-1 siRNA and negative control siRNA. As 
shown in Fig. 3A, cyclin E1 levels decreased 
after treatment with Bmi-1 siRNA. This suggests 
that cyclin-E1 suppression is mediated via Bmi-1. 
Furthermore, Figure 3B shows that attenuation of 
Bmi-1 resulted in G1-cell cycle arrest. Flow 
cytometry data revealed that 51.2 ± 2.5 and 71.4 
± 4.5 % of cells were in G1 phase before and 
after Bmi-1 siRNA treatment, respectively. 
 
 
Figure 3: Reduction of Bmi-1 reduced cyclin E1 
expression and increased the number of cells in 
G1. A. Knock-down of Bmi-1 reduced cyclin E1 
using negative control siRNA. B. Depletion of 
Bmi-1 increased the numbers of cells in G1 




Since puerarin was first isolated from Gegen in 
1950, its pharmacological activity has been 
widely investigated. Puerarin treatment has been 
shown to have beneficial effects on 
cardiovascular disease, CNS disorders, 
Parkinson’s disease (PD), Alzheimer’s disease 
(AD), cancer, and diabetes, and to suppress 
serum ALT and AST levels and Bcl-2 mRNA 
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expression [16, 18]. Moreover, it has also been 
found to stimulate apoptosis in activated hepatic 
stellate cells in rats with liver fibrosis induced 
with CCl4. The viability of acute myeloid leukemia 
cell lines, including U937, Kasumi-1, HL-60, and 
NB4 cells, was considerably decreased after 
treatment with puerarin via inhibition of the cell 
cycle. Further studies confirmed the role of 
puerarin in the reduction of motility migration, 
adhesion, and invasion of human HO-8910 
omophoria cells [19]. More recently, puerarin has 
been shown to decrease the apoptosis of retinal 
pigment epithelial cells by preventing damage in 
peroxynitrites [20]. Thus, the effect of puerarin on 
retinoblastoma cells and the possible 
mechanisms of action was explored [15].   
 
Retinoblastoma is a rare form of cancer that 
affects the retina in children. Unfortunately, we 
are still facing challenges and hurdles in treating 
this disease effectively. Therefore, it is necessary 
to find novel agents for retinoblastoma 
management. The initial part of this study was 
aimed at defining the effect of puerarin on the 
cellular viability of human retinoblastoma Y79 
cells. The results showed that cell viability was 
significantly diminished after puerarin treatment 
in a concentration-dependent manner. The 
results confirmed that puerarin has anti-
proliferative effects. Next, we investigated the 
effect of puerarin on the cell cycle. The flow 
cytometry results suggest that puerarin 
significantly increases the number of Y79 cells in 
G1 phase in a concentration-dependent manner.  
 
Cyclins (cyclins D and E), which are activated 
through cyclin-dependent kinase (Cdk) enzymes, 
play a vital role in the progression of the cell 
cycle. The E type cyclins (E1 and E2) initiate 
entry into S-phase and are required for G1/S cell 
cycle development. Therefore, inhibition of E 
cyclins are a potentially lucrative target for 
inhibition of tumorigenesis in human 
retinoblastoma Y79 cells. We found that puerarin 
inhibits the expression of cyclin E1. Various 
studies have confirmed the role of the signaling 
pathway in the down regulation of cyclin E1 [17]. 
Therefore, we investigated the effect of puerarin 
on mTOR expression. 
 
mTOR plays a critical role in the metabolism, 
growth, and proliferation of cells, and is a novel 
target for anticancer agents. The results of this 
study show that puerarin inhibited the growth of 
human retinoblastoma Y79 cells by 
downregulating Bmi-1 protein and mRNA through 
mTOR inhibition. These results are similar to 
those reported in previous studies, and suggest 
that puerarin can inhibit the progress of 
retinoblastoma through inhibition of mTOR. 
CONCLUSION 
 
This study showed that puerarin has beneficial 
effects on human retinoblastoma Y79 cells. 
Downregulation of Bmi-1 protein and mRNA 
expression through mTOR inhibition may be a 
possible mechanism for the anti-proliferative 
effect of puerarin in human retinoblastoma Y79 
cells. The findings also indicate that puerarin 
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